Pandion raises $58mm in Series A round
Executive Summary
Pandion Therapeutics Inc. (bispecific antibodies for inflammatory and autoimmune diseases) raised $58mm through its Series A round. Seed investor Polaris Partners co-led the round, alongside Versant Ventures and Roche Venture Fund. BioInnovation Capital and SR One also took part.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice